{"id":"bpaq","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BPaQ represents a pharmaceutical formulation strategy by Otsuka to enhance drug absorption and efficacy through prodrug technology. The exact active moiety and mechanism require further clinical characterization, but the approach aims to optimize pharmacokinetic properties for improved patient outcomes in its target indication.","oneSentence":"BPaQ is a prodrug formulation designed to improve the oral bioavailability and therapeutic delivery of its active moiety.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:08.484Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07209761","phase":"PHASE3","title":"A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-16","conditions":"Pulmonary Tuberculosis","enrollment":532},{"nctId":"NCT07393074","phase":"NA","title":"PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-01","conditions":"Hepato Cellular Carcinoma, Cirrhosis, Autonomic Nervous System","enrollment":100},{"nctId":"NCT05144113","phase":"","title":"FES-Rowing: Preventing the Secondary Conditions of Paralysis Through Vigorous Exercise","status":"COMPLETED","sponsor":"Spaulding Rehabilitation Hospital","startDate":"2021-03-16","conditions":"Paralysis, Legs","enrollment":20},{"nctId":"NCT04353700","phase":"NA","title":"Effects of a 12-week Home-based Yoga on Bone and Cardiovascular Health","status":"COMPLETED","sponsor":"University of Massachusetts, Lowell","startDate":"2018-09-19","conditions":"Osteoporosis, Cardiovascular Risk Factor","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":183,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bedaquiline, Pretomanid, Quabodepistat"],"phase":"phase_3","status":"active","brandName":"BPaQ","genericName":"BPaQ","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}